Sembcorp finalises $6.5B takeover of Alinta Energy
Singaporean energy giant Sembcorp has finalised its landmark $6.5 billion takeover of Alinta Energy.

Finance journalist at Grafa with years of experience covering Asia-Pacific financial markets at S&P Global, Mortgage Ezy, and GMA Network.
Singaporean energy giant Sembcorp has finalised its landmark $6.5 billion takeover of Alinta Energy.
Syndax Pharmaceuticals (NASDAQ:SNDX) unveiled a broad array of clinical data reinforcing the therapeutic profile of its approved blood cancer drug, Revuforj, across several distinct mutations and stages of acute leukemia.
Dana Incorporated (NYSE:DAN) has reached a definitive agreement to combine with Eaton's (NYSE:ETN) Mobility business, a blockbuster industrial carve-out that values the division at $5.1 billion and establishes a premier global vehicle powertrain supplier.
Hooker Furnishings (NASDAQ:HOFT) reported a return to profitability for its fiscal 2027 first quarter, driven by sharp gross margin expansion and resilient performance across its core segments, even as soft consumer demand continues to drag on top-line retail furniture sales.
Norfolk Metals (ASX:NFL) announced the acquisition to secure a 100% interest in the Ciclón Copper Project in Chile.
An artificial intelligence researcher known as "Pliny the Liberator" claims to have bypassed the safety guardrails of Anthropic's newly released Claude Fable 5 model less than two days after its launch.
Prescient Therapeutics (ASX:PTX) announced the appointment of Dr Rosalind Wilson as its new Chief Medical Officer, effective July 13.
Kingston Resources (ASX:KSN) announced the permanent cessation of mining activities at its Pearse South open pit.
A Canadian teenager has pleaded guilty to his role in a cryptocurrency fraud scheme that stole more than $13 million from victims and funded a lavish lifestyle involving luxury cars, private jets and expensive accommodation.
Aurora Cannabis (NASDAQ:ACB) reported record global medical cannabis net revenue and adjusted EBITDA for fiscal year 2026, capitalizing on its structural pivot toward high-margin prescription markets in Europe and Australia.